Jan 24 |
Shattuck Labs files to sell 3.1M shares for its holders
|
Jan 8 |
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
Jan 8 |
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
|
Jan 4 |
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 18 |
Shattuck Labs: Early Positive Data May Be A Harbinger Of Good Things
|
Dec 14 |
Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
|
Dec 13 |
Dow Jumps Over 200 Points; Federal Reserve Holds Interest Rates Steady
|
Dec 13 |
Shattuck Labs stock rallies 90% on Phase 1 data for blood cancer drug
|
Dec 13 |
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) ...
|
Dec 5 |
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation...
|